Ligand Pharmaceuticals Incorporated (LGNDZ)
| Market Cap | 4.03B +74.6% |
| Revenue (ttm) | 268.09M +60.4% |
| Net Income | 124.45M |
| EPS | 6.13 |
| Shares Out | n/a |
| PE Ratio | 32.35 |
| Forward PE | 21.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,245 |
| Average Volume | 120,522 |
| Open | 0.0020 |
| Previous Close | n/a |
| Day's Range | 0.0020 - 0.0020 |
| 52-Week Range | 0.0006 - 0.0129 |
| Beta | 1.04 |
| RSI | 36.44 |
| Earnings Date | Feb 11, 2026 |
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]
Financial Performance
Financial StatementsNews
Ligand to Participate in March Investor Conferences
JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share 1 of $...
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday,...
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi...
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over...
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come
Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a ke...
Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated ( LGND) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Fina...
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) an...
Ligand to Participate in November Investor Conferences
JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi...
Impax Small Cap Fund Q3 2025 Contributors And Detractors
Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asse...
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 20...
Ligand to Host Investor Day on December 9, 2025
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9...
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17 th Captisol-enabled™ approved product JUPITER, Fla....
Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc (“Arecor” or the “Compan...
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi...
Ligand Announces Closing of Convertible Senior Notes Offering
JUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0...
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convert...
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of conve...
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Lauren Hay - Corporate Participant Melanie Herman - Corporate Partici...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) an...
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to i...
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 202...
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially la...